Industrifonden
VC Fund
Stockholm, Sweden
Industrifonden is a Nordic evergreen venture capital firm with a fund size of $600m, that focuses on early-stage technology and life science companies with international potential. The company works long term with the entrepreneurs we invest in, and have a strong track record of building game changing companies. Industrifonden-backed companiesinclude tech companies Qlik, Arcam, Soundtrack Your Brand, Fishbrain, and life science companies CellaVision, Oncopeptides and AMRA.
- Total investments:
- 204
- Last investment:
- Lead investor:
- 40%
Last updated:
For AI agents: llms.txt
Industries Industrifonden invests in
Stages Industrifonden invests in
Countries Industrifonden invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 17 contacts → | |||
Round size
- Series A
- $3.3M–$21M
- Venture - Series Unknown
- $2.3M–$20M
Investment Focus
Industry
- Biotechnology 24 (12%)
- Software 23 (11%)
- Information Technology 15 (7%)
- Health Care 12 (6%)
- Energy 10 (5%)
Stage
- Series A 39 (19%)
- Funding Round 38 (19%)
- Venture - Series Unknown 33 (16%)
- Seed 25 (12%)
- Series B 15 (7%)
Country
- Sweden 93 (46%)
- United States 6 (3%)
- Denmark 4 (2%)
- Norway 2 (1%)
- Poland 1 (0%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Anna Ljungdahl
Investment Manager
|
Investment Manager | Total investments: 6 | Find email | |
Bita Sehat
Investment Manager of Life Science
|
Investment Manager of Life Science | Total investments: 4 | Find email | |
Hadar Cars
Senior Investment Director
|
Senior Investment Director | Total investments: 22 | Find email | |
Hansson Lennart
Business Unit Manager Life Science
|
Business Unit Manager Life Science | Total investments: 2 | Find email | |
Jonas Jendi
Investment Director
|
Investment Director | Total investments: 2 | Find email | |
| See all 17 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| AnaCardio is a clinical stage biopharmaceutical company developing novel drugs to treat heart failure. | $70.8M / Series B / Sep 30, 2026 | ||
| EnginZyme is a biotechnology company that specializes in biocatalysis. It creates products for easy and cost-efficient implementation of biocatalytic processes and helps the chemical industry transition to a sustainable way of operating.The company is driven by a mission to make biocatalysis the first choice for chemical process designersworldwide. | $7.6M / Venture - Series Unknown / Sep 22, 2026 | ||
| Pixelgen Technologies develops technologies for biomedical research and diagnostics. Pixelgen Technologies was founded in 2020 and was headquartered in Sweden. | $15.5M / Series B / Aug 20, 2026 | ||
| Cellevate is an innovative biotech company that develops the next generation of cell culture systems. | $2.2M / Seed / Mar 30, 2026 | ||
| Vesiro enables companies to scale their databases with increased performance. | $1.9M / Seed / Feb 10, 2026 | ||
| Melt&Marble, formerly known as Biopetrolia, was founded patent holding firm for co-founder Professor Jens Nielsen’s research group. | $8.5M / Series A / Dec 08, 2025 | ||
| SaltX NCS is the underlying technology driving the future of thermal energy storage. | $10.5M / Post-IPO Equity / Nov 25, 2025 | ||
| AlixLabs offers nanostructure fabrication methods using the atomic layer etching process. This method of nanostructure fabrication uses the atomic layer etching process, which is a damage-free etch process. AlixLabs offers an ALE-based method for producing nanostructures with characteristic sizes less than 20 nm. AlixLabs' technologyfabricates nanostructures beyond the resolution limit of optical and electron beam lithography, with applications in nanoelectronic device fabrication, for example. This invention, among other things, may enable an economically viable method of transistor channel scaling for sub-20 nm technology nodes. | $17.3M / Series A / Nov 20, 2025 | ||
| BOOST Pharma is a biotechnology research company developing a stem cell therapy for the treatment of osteogenesis imperfecta. It is based on novel mesenchymal stem cells that have high bone-forming capabilities that migrate to the bone of patients where they will engraft, and start bone formation.It was founded in 2019 and is headquartered inCopenhagen, Denmark. | $1.6M / Convertible Note / Oct 28, 2025 | ||
| Arevo offers liquid and granular amino acid fertilizer technologies for faster and better plant establishment. | $8.5M / Venture - Series Unknown / Oct 17, 2025 | ||
| See all 204 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Industrifonden invest in?
Industrifonden invests primarily in Biotechnology, Software and Information Technology startups, most often at Series A and Funding Round stage. Most of the 204 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Industrifonden's check size?
Industrifonden typically joins rounds of $3.3M–$21M at Series A and $2.3M–$20M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Industrifonden participates in.
How do I contact Industrifonden?
Public channels for Industrifonden include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Industrifonden?
The team at Industrifonden includes Anna Ljungdahl (Investment Manager), Bita Sehat (Investment Manager of Life Science) and Hadar Cars (Senior Investment Director), among 17 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
